Evusheld (Tixagevimab and Cilgavimab) for the Pre-exposure Prophylaxis of COVID-19 in Adults and Adolescents (≥ 12 Years of Age and Weighing at Least 40 kg)

Details

Files

Project Status:

Completed

Project Line:

Health Technology Review

Project Sub Line:

Technology Review

Project Number:

HD0008-000

Tixagevimab and cilgavimab (Evusheld) is a combination of long-acting monoclonal antibodies for intramuscular administration that provides pre-exposure prophylaxis against COVID-19 for people at risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who have not had a known recent exposure to an individual infected with SARS-CoV-2. Canada's Drug Agency conducted a review of the evidence and convened an Implementation Advice Panel to prioritize the patient populations that are most likely to benefit from pre-exposure prophylaxis with Evusheld.

Files

Evusheld (Tixagevimab and Cilgavimab) for the Pre-exposure Prophylaxis of COVID… View PDF

Last Updated : April 21, 2022